Holen Sie sich die Stockscreener-App
13.99
7.89%
1.004
Schlusskurs vom Vortag:
$12.99
Offen:
$12.72
24-Stunden-Volumen:
2.90M
Relative Volume:
2.77
Marktkapitalisierung:
$757.66M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-8.857
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
+56.59%
1M Leistung:
+83.68%
6M Leistung:
+96.84%
1J Leistung:
+249.50%
1-Tages-Spanne:
$12.07
$15.29
1-Wochen-Bereich:
$8.63
$15.74
52-Wochen-Spanne:
$2.315
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie FULC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
14.00 | 703.00M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.32 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.40 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
416.85 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
894.11 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.54 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-07-29 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
FULC: Analyst Rating Maintained by B of A Securities, Price Targ - GuruFocus
Fulcrum Therapeutics (FULC) Is Up 31.6% After $150M Stock Offering Following Positive Pociredir Data - Yahoo Finance
Fulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial - MSN
Fulcrum Therapeutics dips after unveiling $150 million share sale - TradingView
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock - MSN
Fulcrum Therapeutics (FULC) Launches $150M Public Stock Offering - GuruFocus
Fulcrum stock drops after announcing $150 million public offering By Investing.com - Investing.com Australia
Fulcrum Therapeutics launches $150 million common stock offering - Investing.com
Fulcrum stock drops after announcing $150 million public offering - Investing.com
Fulcrum Therapeutics launches $150 million common stock offering By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Launches $150 Million Common Stock Offering - marketscreener.com
Fulcrum Therapeutics (Nasdaq: FULC) starts proposed $150.0M raise, plus $22.5M option - Stock Titan
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛
BofA Securities raises Fulcrum Therapeutics stock price target on SCD drug data - Investing.com Canada
Fulcrum Therapeutics’ Promising Surge: Analyzing Recent Progress - StocksToTrade
The growth track for Fulcrum Therapeutics Inc (FULC) has changed recently - Setenews
Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results - inkl
Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Stifel raises Fulcrum Therapeutics stock price target to $25 on strong ASH data - Investing.com Canada
Fulcrum Therapeutics (NASDAQ:FULC) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
Fulcrum Therapeutics jumps after trial data of blood disorder drug - TradingView
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
FULC: Cantor Fitzgerald Raises Price Target to $24, Maintains Ov - GuruFocus
FULC: RBC Capital Raises Price Target to $10, Maintains Sector P - GuruFocus
Piper Sandler Raises Price Target and Reiterates Overweight Rati - GuruFocus
Is Fulcrum Therapeutics Stock Set to Skyrocket? - timothysykes.com
Goldman Sachs reiterates rating on Fulcrum Therapeutics stock after positive trial data - Investing.com UK
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
FULC Stock Sees Analyst Rating Update from HC Wainwright | FULC - GuruFocus
Fulcrum Therapeutics stock price target raised to $23 from $16 at Piper Sandler - Investing.com UK
Why Fulcrum Therapeutics Stock Is Surging Nearly 50% Today? - Tokenist
RBC Raises Price Target on Fulcrum Therapeutics to $10 From $7, Keeps Sector Perform, Speculative Risk - marketscreener.com
Fulcrum Therapeutics stock price target raised to $25 from $18 at H.C. Wainwright - Investing.com UK
Fulcrum Therapeutics (FULC) Surges on Promising Trial Results - GuruFocus
Fulcrum Therapeutics Announces Initial Results from Phase 1b PIONEER Trial of Pociredir - TradingView
Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results - MSN
Fulcrum Stock Nears 2024 Highs: Early Stage Sickle-Cell Data Sparks Target Price Hikes - Stocktwits
Fulcrum Therapeutics stock price target raised to $10 from $7 at RBC Capital - Investing.com Canada
Fulcrum Therapeutics (FULC) Sees Promising Results in Sickle Cel - GuruFocus
Fulcrum reports positive results for sickle cell drug pociredir - Investing.com India
Fulcrum reports positive results for sickle cell drug pociredir By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics Reports Positive Initial Results from Phase 1b PIONEER Trial of Pociredir for Sickle Cell Disease - Quiver Quantitative
Fulcrum Therapeutics (Nasdaq: FULC) 20 mg pociredir sends 58% of SCD patients to ≥20% HbF at Week 6 - Stock Titan
Fulcrum Therapeutics (Nasdaq: FULC) issues options at $9.87 under 2022 inducement plan - Stock Titan
How strong is Fulcrum Therapeutics Inc. stock balance sheetTrade Volume Summary & Entry Point Confirmation Signals - Newser
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7.7%Here's What Happened - MarketBeat
Will Fulcrum Therapeutics Inc. stock benefit from green energy trends2025 Top Decliners & Weekly Return Optimization Plans - Newser
A History of Outperforming Analyst Forecasts and Beating the Odds: Fulcrum Therapeutics Inc (FULC) - Setenews
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 - The Manila Times
Will Fulcrum Therapeutics Inc. stock remain a Wall Street favorite2025 Performance Recap & Advanced Technical Analysis Signals - Newser
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.25%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):